Nuvalent, Inc. (NASDAQ: NUVL) is a biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company is making strides in the oncology sector, particularly with its drug neladalkib, which is being tested for effectiveness in treating advanced ALK-positive non-small cell lung cancer (NSCLC). Nuvalent's competitors include other biotech firms working on similar cancer therapies.
On November 17, 2025, Leerink Partners set a price target of $149 for NUVL, suggesting a potential upside of 34.77% from its current price of $110.56. This optimistic outlook is supported by Nuvalent's recent announcement of promising topline results from its ALKOVE-1 Phase 1/2 trial. The trial evaluated neladalkib in patients with advanced ALK-positive NSCLC, showing a 31% response rate among 253 patients.
The trial results are significant as they involve patients who had previously been treated with tyrosine kinase inhibitors (TKIs) and, in many cases, chemotherapy. The recommended Phase 2 dose of neladalkib is 150 mg once daily, determined during the Phase 1 dose-escalation stage. This indicates potential for further clinical development in this heavily pretreated patient population.
NUVL's stock price is currently $110.11, reflecting a 14.10% increase or $13.61. The stock has fluctuated between $93.30 and $112.52 today, with a 52-week high of $112.53 and a low of $55.54. The company's market capitalization is approximately $8 billion, and the trading volume for the day is 1,681,393 shares on the NASDAQ exchange.
